A budget impact model for a drug in heart failure: Eplerenone

British Journal of Cardiology

Volumn 15, Issue 2, 2008, Pages 101-105

  Duerden, Martin ^a   Tabberer, Maggie ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Budget impact model; Direct costs; Eplerenone; Heart failure

Indexed keywords

EPLERENONE;

ARTICLE; BUDGET; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HEART FAILURE; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; NONBIOLOGICAL MODEL; PATIENT CARE; PRIMARY MEDICAL CARE; UNITED KINGDOM;

EID: 42049104912     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. National Institute for Health and Clinical Excellence. NICE Guideline Number 5. Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: NICE, October 2003. Full guideline, available from: www.nice.org.uk [accessed 17/01/08].
2. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:609-21.
3. Inspra (eplerenone) Summary of Product Characteristics. Pfizer Ltd., 2007.
4. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
5. Gheorghiade M, Pitt B, Chu T-C, Patni R. Length of stay for heart failure hospitalisation in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Eur J Heart Failure 2004;3(suppl 1):115, Abstract 455.
6. Office of National Statistics. National Population Projections. Available from: http://www.statistics.gov.uk/cci/nugget.asp?id=1352 [accessed 15/01/08].
7. Department of Health. NHS reference costs 2005-2006, Appendix 4. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_062884 [accessed 15/01/08].
8. ISD Scotland. Scottish health statistics. Available from: http://www.isdscotland.org/isd/ information-and-statistics.jsp?pContentID=3075&p_applic= CCC&p_service=Content.show&Table IC2 [accessed 17/01/08].
9. National Institute for Health and Clinical Excellence. Costing Report NICE clinical guideline 48. MI: secondary prevention. London: NICE, May 2007. Available from: www.nice.org.uk [accessed 17/01/08].
10. Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000;83:505-10.
11. Steg PG, Dabbous OH, Feldman LJ et al.; for the GRACE investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE) Circulation 2004; 109:494-9.
12. Haymarket Publishing. eMIMS. Available from: http://www.emims.net
13. Department of Health. The NHS Improvement Plan. Cm 6268. London: Stationery Office, 2004.
14. Murphy E. Case management and community matrons for long term conditions. BMJ 2004;329:1251-2.
15. Department of Health. Supporting People with Long Term Conditions. An NHS and Social Care Model to Support Local Innovation and Integration. January 2005. Available from: www.dh.gov.uk [accessed 17/01/08].
16. Rawlins DR, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
17. Weintraub WS, Zhang Z, Mahoney EM et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005;111:1106-13.
18. Lee WC, Chavez YE, Baker T, Luce BR. Economic burden of heart failure: a summary of recent literature. Heart Lung 2004;33:362-71.